Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.

MLA

Röth, Alexander, et al. “Sutimlimab in Patients with Cold Agglutinin Disease: Results of the Randomized Placebo-Controlled Phase 3 CADENZA Trial.” Blood, vol. 140, no. 9, Sept. 2022, pp. 980–91. EBSCOhost, https://doi.org/10.1182/blood.2021014955.

APA

Röth, A., Berentsen, S., Barcellini, W., D’Sa, S., Jilma, B., Michel, M., Weitz, I. C., Yamaguchi, M., Nishimura, J.-I., Vos, J. M. I., Storek, M., Wong, N., Patel, P., Jiang, X., Vagge, D. S., Wardęcki, M., Shafer, F., Lee, M., & Broome, C. M. (2022). Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood, 140(9), 980–991. https://doi.org/10.1182/blood.2021014955

Chicago

Röth, Alexander, Sigbjørn Berentsen, Wilma Barcellini, Shirley D’Sa, Bernd Jilma, Marc Michel, Ilene C Weitz, et al. 2022. “Sutimlimab in Patients with Cold Agglutinin Disease: Results of the Randomized Placebo-Controlled Phase 3 CADENZA Trial.” Blood 140 (9): 980–91. doi:10.1182/blood.2021014955.